bluuebunny/crossref_metadata_2025_split huggingface dataset:
Prevalence and prognosis of severe tricuspid regurgitation in patients with atrial fibrillation with normal left ventricular systolic function
Authors: Prapan N , Ratanasit N 
Published: November 2020

Abstract

Background
Significant functional tricuspid regurgitation (FTR) can be found in some patients with atrial fibrillation (AF). The results of the previous studies are still controversial whether significant FTR in patients with AF can cause worse outcomes such as heart failure or death.

Purpose
To study the prevalence, predictors and prognosis of significant FTR in patients with AF with normal left ventricular (LV) systolic function.

Methods
We conducted a retrospective cohort study in patients with AF and normal LV ejection fraction (LVEF) from May 2013 through January 2018. Significant FTR was defined as moderate to severe FTR. Pulmonary hypertension (PH) was defined as right ventricular systolic pressure &gt;50 mmHg or mean pulmonary artery pressure &gt;25 mmHg. We evaluated the prevalence of significant FTR and evaluated the adverse outcomes between significant and insignificant FTR groups. The adverse outcomes were defined as heart failure visit or hospitalization and all cause death within 2 years of follow up. We also evaluated the factors associated with significant FTR in AF patients.

Results
There were 498 patients with AF and 300 (mean age 68.8±10.8 years, 50% female) were included in the study. Paroxysmal, persistent and permanent AF were found in 34.7%, 44.7% and 20.6% respectively. Mean LVEF was 65.3±6.3%. PH and significant FTR were reported in 30.7% and 21.7%, respectively. All cause death and heart failure (visit and hospitalization) were found in 26 (8.7%) and 39 (13%) patients, respectively. There was no statistically significant difference in death between patients with significant and insignificant FTR (12.3% vs. 7.7%; 95% confidence interval (CI) 0.70–4.08, p=0.24). Patients with significant FTR had heart failure more often than those with insignificant FTR (61.5% vs. 38.5%; 95% CI 4.15 - 17.75, OR 8.58, p&lt;0.001). The multivariate analysis showed that the predictors of significant FTR were female gender, permanent AF and presence of PH (OR 2.5, 3.6 and 6.1, respectively). The predictors of the adverse outcomes in patients with AF were high CHA2DS2-VASc score (95% CI 1.09 - 1.92, p=0.01) and significant FTR (95% CI 9.61 - 698.17, p&lt;0.01).

Conclusions
Significant FTR was common in patients with AF and associated with heart failure outcomes. Female gender, permanent AF and presence of PH were independent predictors of significant FTR, while high CHA2DS2-VASc score and significant FTR were independent predictors of the adverse outcomes in patients with AF and normal LVEF.

Funding Acknowledgement
Type of funding source: None
How is juvenile rheumatic heart disease different: baseline results from a prospective north Indian registry
Authors: Mahajan K , Prakash Chand Negi D.R 
Published: November 2020

Abstract

Introduction
Juvenile rheumatic heart disease (RHD) refers to RHD in patients &lt;20 years of age. There are no contemporary data highlighting the differences between juvenile and older RHD patients.

Purpose
We aim to report the age related differences in the pattern, and consequencies of valvular dysfunction in patients of RHD.

Methods
The 2475 consecutive patients of RHD diagnosed using clinical and echocardiographic criteria were registered prospectively from 2011 till December 2019. Patients were divided into 3 groups according to their age: Group 1 (Juvenile RHD), Group 2 (21–50 years), and Group 2 (&gt;51 years).The data concerning the socio-demographic and clinical profile were recorded systematically, and the nature and severity of valvular dysfunction was assessed by echocardiography. The data were analyzed using the Epi-InfoTM Software.

Results
Out of 2475 RHD patients, Juvenile RHD comprised of 211 (8.5%) patients. Group 2 and 3 comprised of 1691 (68.3%) and 573 (23.2%) patients respectively. Overall, 1767 (71.4%) patients were females, however this female predilection was less pronounced in juvenile RHD (55.5% females vs 44.5% males) as compared to older groups. Past history of acute rheumatic fever was more commonly recorded in Juvenile RHD group (37.9% vs 18.8% in group 2 and 10% in group 3, p=0.0001). At the time of registration, the presence of advanced heart failure symptoms (dyspnea class III and IV) (11.4% group 1 vs 13.9% group 2 vs 20.6% group 3, p&lt;0.0001), right heart failure symptoms (0.9% group 1 vs 2.5% group 2 vs 7.3% group 3, p&lt;0.01), thromboembolic events (0% group 1 vs 4.1% group 2 vs 3.3% group 3, p&lt;0.01), atrial fibrillation (2.8% group 1 vs 24.5% group 2 vs 45.9% group 3, p&lt;0.0001), and pulmonary hypertension (27.1% group 1 vs 40.3% group 2 vs 51.9% group 3, p&lt;0.01), were all more commonly recorded in non-juvenile older RHD groups. Multivalvular involvement was also less common in juvenile RHD (34.6% vs 42.4% and 44.5%, p=0.04). Mitral regurgitation was the most common lesion in Juvenile RHD followed by aortic regurgitation (68.7% and 40.2% respectively). Stenotic lesions (both mitral and aortic) were present more commonly in older age groups.

Conclusion
RHD is predominantly a disease of females, however the predilection is less common in juvenile patients. Juvenile RHD predominantly affects the mitral valve and mainly leads to regurgitant lesions. As the age advances, the complications of RHD, mainly heart failure symptoms, thromboembolic events, pulmonary hypertension, and atrial fibrillation, become more common.

Funding Acknowledgement
Type of funding source: Public hospital(s). Main funding source(s): Self sponsored registry
Bleeding complications drive early mortality of patients with atrial fibrillation after transcatheter aortic valve replacement
Authors: Stachon P , Lother A.L , Kaier K.K , Zehender M.Z , Bode C.B , Von Zur Muehlen C.M 
Published: November 2020

Abstract

Background and objectives
Atrial fibrillation is a risk factor for poor post-operative outcome after transfemoral transcatheter aortic valve replacement (TF-TAVR). The present study analyses the outcomes after TF-TAVR in patients with or without atrial fibrillation (AF) and identifies independent predictors for in-hospital mortality in clinical practice.

Methods and results
Among all 57,050 patients undergoing isolated TF-TAVR between 2008 and 2016 in Germany, 44.2% of patients (n=25,309) had AF. Patients with AF were at higher risk for unfavorable outcome after TAVR. Including all baseline characteristics for a risk-adjusted comparison, AF was an independent risk factor for in-hospital mortality after TAVR. Among patients with AF, EuroSCORE, NYHA class or renal disease had only moderate effects on mortality, while the occurrence of post-procedural stroke substantially increased in-hospital mortality (OR 3.55, 95% CI 2.77–4.56, P&lt;0.001). However, the strongest independent predictor for in-hospital mortality among patients with AF was bleeding (OR 11.04, 95% CI 9.53–12.80, P&lt;0.001). Bleeding also was by far the strongest predictor for prolonged mechanical ventilation (OR 25.36, 95% CI 21.83–29.48, P&lt;0.001).

Conclusions
The present study demonstrates that the incidence of bleeding defines the early outcome of patients with AF after TF-TAVR. Thus, the peri-procedural phase demands particular care in anti-thrombotic regimen.

Funding Acknowledgement
Type of funding source: None
Impact of on-clopidogrel platelet reactivity on incidence of peri-interventional bleeding in patients undergoing transcatheter aortic valve implantation
Authors: Kille A , Nuehrenberg T , Hromek J , Valina C.M , Trenk D , Neumann F.J , Hochholzer W 
Published: November 2020

Abstract

Background
Transcatheter aortic valve implantation (TAVI) has become clinical routine for patients at intermediate to high risk for surgical aortic valve replacement. The optimal antithrombotic strategy following TAVI is still not well defined. Antithrombotic treatment is administered to prevent hypo-attenuated leaflet thickening, valve thrombosis, or ischemic stroke. However, most of these patients are also at high risk for bleeding. Current guidelines recommend dual antiplatelet therapy although the clinical evidence is limited.

Methods
This analysis enrolled patients undergoing TAVI from 11/2013 until 04/2018. Patients were either on long-term dual antiplatelet therapy with clopidogrel and aspirin or received a loading dose 300 to 600mg of clopidogrel and 400mg aspirin before TAVI. Platelet reactivity was determined by multi-electrode impedance aggregometry after stimulation with arachidonic acid and adenosine diphosphate (ADP) before TAVI as well as at day 1 and 5 thereafter. Peri-interventional bleeding was assessed up to 5 days following TAVI and coded according to BARC-classification.

Results
The present analysis included 484 patients (median age 83 [79–86] years; female sex 54.5%). There were 199 (41.1%) patients with a bleeding event. Most frequent were BARC 2 bleedings in 117 (24.2%) cases followed by BARC 1 (6.0%), BARC 3b in 25 (5.2%) and BARC 3a in 22 (4.5%) cases. On-clopidogrel platelet reactivity tested after stimulation with ADP was significantly lower in patients with bleeding events as compared to patients without bleeding (Figure). No differences were observed in arachidonic acid-induced platelet reactivity as marker for aspirin-efficacy between both groups over time. Multivariate logistic regression analysis identified on-clopidogrel platelet reactivity and use of oral anticoagulation as strongest independent predictors for bleeding events.

Conclusion
On-clopidogrel platelet reactivity is an independent predictor for peri-interventional bleeding in patients undergoing TAVI. Taken together with previous data indicating no association of on-clopidogrel platelet reactivity with peri-interventional ischemic events, the present data question the need for a strong peri-interventional dual antiplatelet therapy in patients undergoing TAVI.

Funding Acknowledgement
Type of funding source: None
Feasibility and safety of oversizing self-expandable valves for transcatheter aortic valve implantation, according to aortic annulus maximal diameter
Authors: Jourdi B , Trimech T.R , Fradi S , Ghostine S 
Published: November 2020

Abstract

Background
Transcatheter aortic valve implantation (TAVI) can lead to paravalvular leak (PVL) in 15% to 20% of cases, which remains an important prognostic factor and an independent predictor of mortality in short and long-term follow-up.

Objectives
To evaluate feasibility and safety of oversizing Medtronic Self-Expandable Valve (Dvalve), calculated according to the aortic annulus maximal diameter (Dmax), on the incidence of PVL and in-hospital mortality after TAVI.

Methods
We retrospectively analyzed the data of 610 patients treated with TAVI between January 2016 and December 2018. A group of 45 patients of the oversized group (October 2017 to December 2018) accordingly to the Dmax, when (Dvalve − Dmax) | &lt;2 mm in the absence of contraindication was compared to a control group of 213 patients whose prosthesis size had been chosen according to the aortic annulus perimeter (January 2016 to September 2017).

Results
In the “oversized” group, no patient had a significant PVL after TAVI compared with the control group (0% vs. 7.51%; p=0.041). Balloon post-dilatation was significantly less frequent in the “oversized” group (0% vs. 10.3%; p=0.012). Per-procedural irradiation and the average length of in-hospital stay were significantly lower (PDS = 2,296.05±1,667.94 cGy·mm2 vs. 4,568±1,352.84 cGy·mm2; p&lt;0.001; and 5.23±1.74 days vs. 6.33±3.23 days; p=0.029, respectively). No case of annulus rupture occurred in the “oversized” group. The incidences of high-degree atrioventricular block with definitive pacing and in-hospital mortality were similar between the two groups.

Conclusion
Oversizing the self-expandable valve, according to the aortic annulus maximal diameter, significantly reduced PVL after TAVI, balloon post-dilatation, per-procedural irradiation, and the length of hospital stay, without increasing the risk of mechanical, rhythmic, conductive and coronary occlusion complications. It does not increase the in-hospital mortality rate either. Randomized controlled trials are needed to establish a firm conclusion about its feasibility and safety.

Funding Acknowledgement
Type of funding source: None
Real-world comparison of the last generation main balloon-expandable and self-expanding valves in patients undergoing TAVI. Does the type matter?
Authors: Kalogeras K , Ruparelia N , Kabir T , Jabbour R , Kalantzis C , Bei E , Katsianos E , Naganuma T , Nakamura S , Sen S , Malik I.S , Mikhail G , Dalby M , Vavuranakis M , Panoulas V 
Published: November 2020

Abstract

Background/Introduction
The balloon expandable Edwards Sapien-S3 and Ultra, and the self-expanding Medtronic Evolut-Pro and Evolut-R 34mm represent the main volume of transcatheter aortic valve implantation (TAVI) procedures conducted worldwide.

Purpose
In the present study, we aim to compare the peri-procedural and one-year clinical outcomes between these last generation devices.

Methods
Consecutive patients from the ATLAS (Athens-Tokyo-London Aortic Stenosis) registry, who had undergone TAVI with either the S3/Ultra or Evolut-Pro/R 34mm device, in four centers were retrospectively studied. In-hospital procedural characteristics and outcomes were recorded and compared. Kaplan-Meier estimated 1-year all-cause mortality was compared between groups.

Results
In total, 692 patients (352pts treated with S3/Ultra and 340pts with Evolut-Pro/R34mm device) were included in the analysis. Baseline demographics (age, coronary artery disease risk factors, logistic Euroscore and aortic valve hemodynamics) were similar between the two groups.
In terms of peri-procedural and short-term outcomes, patients treated with the Evolut-Pro/R34mm device had significantly lower peak (25.4±3.6mmHg for S3/Ultra vs 14.9±0.6mmHg for the self-expanding valves, p=0.002) and mean (10.7±0.3mmHg S3/Ultra vs 7.9±0.4mmHg Evolut PRO/R34, p&lt;0.001) gradients at discharge.
Conversely, the S3 demonstrated significantly lower rates of at least moderate residual aortic regurgitation (AR) post-operatively (0.3% vs 4.8% for S3 and Evolut-Pro/R34mm respectively, p=0.001). Interestingly, the rate of new permanent pacemaker (PPM) required after the implantation in pacemaker-free patients on baseline, was higher for the S3/Ultra cohort compared to the self-expanding valve group (17.6% vs 11.7% respectively, p=0.054), however not reaching statistical significance yet. As expected, the need for balloon post dilatation of the implanted prosthesis was less among the S3/Ultra patients (5.5% vs 26.1%, p=0.001).
One-year Kaplan-Meier estimated survival was similar between the two groups (85.9% for S3 vs. 90% for Evolut-Pro/R34mm, plog-rank=0.071). Hazard ratio for all-cause mortality (Pro/R34 vs. S3/Ultra) after adjustment for gender and previous MI was similar between the groups (HR=0.73; 95% CI 0.47 to 1.14, p=0.165).

Conclusions
Real life comparison of the last generation balloon expandable and self-expanding devices demonstrates similar 1-year all-cause mortality. The S3/Ultra platforms, as compared to the Evolut-Pro/R34mm, demonstrate less paravalvular leak, at the expense of higher transvalvular gradients. Long-term follow-up and future larger trials are required to establish any potential long-term difference in clinical outcomes and prognosis.

Funding Acknowledgement
Type of funding source: None
Acute response of right ventricular function following transcatheter mitral valve repair
Authors: Sugiura A , Weber M.W , Tabata N.T , Zimmer S.Z , Becher U.B , Tiyerili V.T , Nickenig G.N , Sinning J.M.S 
Published: November 2020

Abstract

Background
Little is known about early right ventricular (RV) response to transcatheter mitral valve repair (TMVR) and its association with clinical outcomes. We assessed the early effect of TMVR on the RV function (RVF) and sought to investigated the prognostic impact of post-procedural RV dysfunction.

Methods
From January 2011 through April 2019, consecutive patients who underwent MitraClip for severe mitral regurgitation were analyzed. We excluded patients in which the evaluation of RVF were un available. RV dysfunction was defined by an RV fractional area change (RVFAC) &lt;35% or tricuspid annular planar systolic excursion (TAPSE) &lt;16 mm. A Cox proportional regression analysis was conducted to investigate the association of post-procedural RV dysfunction with adverse outcomes (all-cause mortality and rehospitalization due to heart failure [HF]).

Results
A total of 403 patients were analyzed.Overall, the mean age was 78 years old and 59% of patients were male. The median left-ventricular ejection fraction (LVEF) was 46.1% [IQR 33.1–59.4], RVFAC was 41.9% [IQR 32.9–49.5], and TAPSE was 17 mm [IQR 14–22]. While 68 patients showed an acute improvement of RVF (35% of patients with baseline RV dysfunction), 51 patients (25% of patients with baseline normal RVF) showed an acute worsening of RVF. In patients with baseline normal RVF, atrial fibrillation (OR 4.57, 95% CI 1.56–13.40, p=0.006, HF duration &gt;18 months (OR 2.95, 95% CI 1.32–6.60, p=0.009), LVEF &lt;50% (OR 3.09, 95% CI 1.32–7.25, p=0.009), and tricuspid regurgitation≥3+ (OR 5.62, 2.28–13.90, p&lt;0.001)were associated with an increased risk of acute worsening of RVF. By contrast, in patients with baseline RV dysfunction, HF duration &gt;18 months (OR 0.43, 95% CI 0.22–0.85, p=0.01) and larger RV volume (OR 0.98, 95% CI 0.97–0.99, p&lt;0.001) were associated with less probability of acute RVF improvement. The event-free survival was significantly different according to the subgroup of variation of RVF (p=0.003). Furthermore, post-procedural RV dysfunction was associated with an increased risk of outcomes (adjusted-HR 2.38, 95% CI 1.28–4.43, p=0.006).

Conclusion
Both acute improvement and worsening of RVF can be observed after TMVR. Post-procedural RV dysfunction is an independent predictor of adverse outcomes.
Event-free survival curve

Funding Acknowledgement
Type of funding source: None
Risk factors and etiology of recurrent mitral regurgitation after edge-to-edge mitral valve repair
Authors: Sugiura A , Weber M.W , Tabata N.T , Oeztuerk C.O , Zimmer S.Z , Becher U.B , Tiyerili V.T , Nickenig G.N , Sinning J.M.S 
Published: November 2020

Abstract

Background
Recurrent MR has been associated with poor prognosis after transcatheter mitral valve repair (TMVR) with the MitraClip system. However, little is known about risk factors and etiology of recurrent mitral regurgitation (MR) after transcatheter edge-to-edge mitral repair with the MitraClip system.

Methods
Among consecutive patients who underwent MitraClip for MR from January 2011 to March 2019, we identified 240 patients who had MR ≤2+ at discharge and follow-up echocardiography within three years after the procedure. Recurrent MR was defined as MR ≥3+ during the follow-up period. To investigate the risk factors for recurrent MR, we conducted a Cox proportional hazard model.

Results
During the follow-up period (median 491 days), 38 patients (15.8%) had recurrent MR (≥3+). The most frequent etiology of recurrent MR was degenerative (n=20, 52.6%), including single leaflet detachment (n=2, 5.3%), loss of leaflet insertion (n=11, 28.9%), and leaflet tear or prolapse (n=7, 18.4%), followed by functional MR (n=18, 47.4%). The risk factors for recurrent MR were greater LV end-diastolic volume (adjusted-HR 1.01, 95% CI 1.00–1.02, p=0.03), higher LV ejection fraction (LVEF) (adjusted-HR 1.05, 95% CI 1.01–1.08, p=0.005), and moderate MR upon discharge (adjusted-HR 2.98, 95% CI 1.50–5.95, p=0.002).After stratification according to the etiology of MR, the association of LVEF was more pronounced in patients with degenerative MR (adjusted-HR 1.07, 95% CI 1.02–1.12, p=0.003), while the association of moderate MR upon discharge was more pronounced in patients with functional MR (adjusted-HR 5.02, 95% CI 1.95–12.8, p&lt;0.001). Furthermore, patients with recurrent MR had an increased antero-posterior annulus diameter regardless of the baseline etiology of the MR.

Conclusions
Greater LV volume, higher LVEF, and moderate MR at discharge were associated with an increased risk of recurrent MR after the MitraClip procedure. A significant increase of the annulus diameter was observed regardless of the baseline etiology of the MR.
Etiology of recurrent MR

Funding Acknowledgement
Type of funding source: None
Prognostic value of pre-operative atrial fibrillation in patients with heart failure and secondary mitral regurgitation undergoing percutaneous mitral valve repair with MitraClip
Authors: Sisinni A , Godino C , Pivato C.A , Adamo M , Taramasso M , Scotti A , Munafo A , Sala A , Curello S , Agricola E , Colombo A , Alfieri O , Maisano F , Metra M , Margonato A 
Published: November 2020

Abstract

Background
Limited data are available regarding the independent prognostic role of atrial fibrillation (AF) after transcatheter mitral valve repair with MitraClip.

Aims
We sought to evaluate the real impact of pre-operative AF in a wide series of patients with heart failure (HF) and secondary mitral regurgitation (MR) after MitraClip treatment.

Methods
The study included 605 patients with severe secondary MR from a multicenter international registry. Patients were stratified into two groups according to the presence or absence of pre-operative AF. The overall prevalence of pre-operative AF was 44%. Primary endpoint was 5-year overall death, secondary endpoints were 5–year cardiac death and first re-hospitalization for acute HF.

Results
At 5-year Kaplan-Meier (KM) analysis conducted in the entire study cohort, compared to patients without AF those with AF had significantly more adverse events in term of overall death (67% vs. 43%; p&lt;0.001) (KM curve A) and cardiac death (65% vs. 37%; p=0.001) (KM curve B) and, moderately more re-hospitalization for acute HF (64% vs. 50%; p=0.048) (KM curve C). To account for baseline differences, patients were propensity score matched 1:1. After matching, 342 adequately matched patients were identified: compared to patients without AF, those with AF had higher rates of death and cardiac mortality but similar rates of re-hospitalization for acute HF.

Conclusion
In this large 5-year analysis of patients with HF undergoing MitraClip treatment for severe secondary MR, AF is common and associated with higher rates of both overall- and cardiac-death. However, AF doesn't seem to affect the benefit of the procedure in term of re-hospitalization for HF.

Funding Acknowledgement
Type of funding source: None